UY32391A - Compuestos amino-heterocíclicos - Google Patents

Compuestos amino-heterocíclicos

Info

Publication number
UY32391A
UY32391A UY0001032391A UY32391A UY32391A UY 32391 A UY32391 A UY 32391A UY 0001032391 A UY0001032391 A UY 0001032391A UY 32391 A UY32391 A UY 32391A UY 32391 A UY32391 A UY 32391A
Authority
UY
Uruguay
Prior art keywords
amino
heterocyclic compounds
formula
compounds
schizophrenia
Prior art date
Application number
UY0001032391A
Other languages
English (en)
Inventor
Michelle Marie Claffey
Patrick Robert Verhoest
Christopher John Helal
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of UY32391A publication Critical patent/UY32391A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos inhibidores de PDE9 de Fórmula y sales farmacéuticamente aceptables de los mismos, en la que R1, R2, R3. A y n son como se definen en este documento. También se proporcionan composiciones farmacéuticas que contienen los compuestos de Fórmula I, y usos de los mismos en el tratamiento de trastornos neurodegenerativos y cognitivos, tales como enfermedad de Alzheimer y esquizofrenia.
UY0001032391A 2009-01-26 2010-01-25 Compuestos amino-heterocíclicos UY32391A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20609209P 2009-01-26 2009-01-26

Publications (1)

Publication Number Publication Date
UY32391A true UY32391A (es) 2010-08-31

Family

ID=42062324

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032391A UY32391A (es) 2009-01-26 2010-01-25 Compuestos amino-heterocíclicos

Country Status (22)

Country Link
US (3) US8278295B2 (es)
EP (1) EP2389382B1 (es)
JP (1) JP5656874B2 (es)
KR (1) KR101417237B1 (es)
CN (1) CN102292340B (es)
AR (1) AR074966A1 (es)
AU (1) AU2010207507B2 (es)
CA (1) CA2748864C (es)
DK (1) DK2389382T3 (es)
ES (1) ES2420860T3 (es)
HK (1) HK1163092A1 (es)
HR (1) HRP20130530T1 (es)
IL (2) IL213923A (es)
MX (1) MX2011007862A (es)
PL (1) PL2389382T3 (es)
PT (1) PT2389382E (es)
SG (1) SG172805A1 (es)
SI (1) SI2389382T1 (es)
TW (1) TWI404721B (es)
UY (1) UY32391A (es)
WO (1) WO2010084438A1 (es)
ZA (1) ZA201105931B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DK2540297T3 (en) 2008-11-19 2015-07-13 Forum Pharmaceuticals Inc The treatment of cognitive disorders with (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CA2761716A1 (en) * 2009-05-11 2010-11-18 Envivo Pharmaceuticals, Inc. Treatment of cognitive disorders with certain alpha-7 nicotinic acid receptors in combination with acetylcholinesterase inhibitors
BR112012029237A2 (pt) 2010-05-17 2016-11-29 Envivo Pharmaceuticals Inc forma cristalina de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida monohidratado
CN103097393B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 喹喔啉化合物
CN103097383B (zh) 2010-09-07 2015-09-16 安斯泰来制药株式会社 吡唑并喹啉化合物
CA2886885C (en) 2011-10-10 2019-07-16 H. Lundbeck A/S Pde9i with imidazo pyrazinone backbone
US9434733B2 (en) 2012-01-26 2016-09-06 H. Lundbeck A/S PDE9 inhibitors with imidazo triazinone backbone
KR20140138694A (ko) 2012-02-03 2014-12-04 테바 파마슈티컬 인더스트리즈 리미티드 최선의 항-TNFα 요법에 실패한 크론병 환자를 치료하기 위한 라퀴니모드의 용도
RU2635522C2 (ru) 2012-05-08 2017-11-13 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции
CN102786525B (zh) * 2012-08-08 2014-12-17 中山大学 N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
WO2014024125A1 (en) 2012-08-08 2014-02-13 Celon Pharma S.A. Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
TW201410244A (zh) * 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
US20150246061A1 (en) * 2012-10-19 2015-09-03 Celus Pharmaceuticals, Inc. Vitamin d analogues for the treatment of a neurological disorder
CN103207246B (zh) * 2012-12-21 2017-10-10 北京万全德众医药生物技术有限公司 一种用液相色谱法分离测定鲁拉西酮及其光学异构体的方法
EP3139924A4 (en) * 2014-05-06 2018-03-07 Anthony G. Visco Methods of treating or preventing preterm labor
MX2016016488A (es) * 2014-08-27 2017-03-30 Hoffmann La Roche Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar).
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
SI3865484T1 (sl) 2015-07-07 2024-05-31 H. Lundbeck A/S Zaviralec pde9 z imidazo pirazinonsko hrbtenico za zdravljenje perifernih bolezni
WO2017019726A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Oxy-cyanoquinolinone pde9 inhibitors
WO2017019724A1 (en) * 2015-07-29 2017-02-02 Merck Sharp & Dohme Corp. Phenyl-cyanoquinolinone pde9 inhibitors
US10376504B2 (en) 2015-07-29 2019-08-13 Merck, Sharp & Dohme Corp. Substituted quinolinones as PDE9 inhibitors
US10662146B2 (en) 2015-09-15 2020-05-26 Praxis Bioresearch, LLC Prodrugs of fencamfamine
CN105467028A (zh) * 2015-11-18 2016-04-06 北京万全德众医药生物技术有限公司 气相色谱法分离测定鲁拉西酮中间体光学异构体的方法
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
WO2018009424A1 (en) 2016-07-06 2018-01-11 Imara, Inc. Pde9 inhibitors for treatment of peripheral diseases
ES2967489T3 (es) * 2016-10-18 2024-04-30 H Lundbeck As Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
SI3532064T1 (sl) 2016-10-28 2020-10-30 H. Lundbeck A/S Kombinirana zdravljenja, ki obsegajo imidazopirazinone za zdravljenje psihiatričnih in/ali kognitivnih motenj
JP2020500841A (ja) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノンの投与を含む併用療法
ES2962865T3 (es) * 2016-11-18 2024-03-21 Integrative Res Laboratories Sweden Ab Nuevos derivados de azetidina útiles como moduladores de la neurotransmisión catecolaminérgica cortical
CN110337437B (zh) 2016-12-28 2023-02-03 达特神经科学有限公司 作为pde2抑制剂的取代的吡唑并嘧啶酮化合物
MX2019010003A (es) * 2017-02-23 2019-12-16 Boehringer Ingelheim Int Nuevo uso medico del compuesto iii.
CN106957300A (zh) * 2017-04-12 2017-07-18 苏州汉德创宏生化科技有限公司 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法
EP3630769A1 (en) 2017-05-22 2020-04-08 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
PT3630772T (pt) * 2017-05-26 2024-02-05 Cardurion Pharmaceuticals Inc Métodos para fabricar e usar inibidores de pde9
CN116585316A (zh) 2017-06-01 2023-08-15 卫材R&D管理有限公司 包含pde9抑制剂的药物组合物
EP3632439B1 (en) * 2017-06-01 2024-03-27 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
MX2019013397A (es) 2017-06-01 2020-02-07 Eisai R&D Man Co Ltd Agente terapeutico para enfermedad con cuerpos de lewy que contiene derivado de pirazoloquinolina.
AU2018276568A1 (en) * 2017-06-01 2019-11-07 Eisai R&D Management Co., Ltd. Dementia therapeutic agent combining pyrazoloquinoline derivative and memantine
AU2018281131B2 (en) 2017-06-08 2022-01-20 Merck Sharp & Dohme Corp. Pyrazolopyrimidine PDE9 inhibitors
KR20200108419A (ko) 2017-11-27 2020-09-18 다트 뉴로사이언스, 엘엘씨 Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
JP2021526134A (ja) 2018-05-25 2021-09-30 イマラ インク． ６−［（３Ｓ，４Ｓ）−４−メチル−ｌ−（ピリミジン−２−イルメチル）ピロリジン−３−イル］−３−テトラヒドロピラン−４−イル−７Ｈ−イミダゾ［ｌ，５−Ａ］ピラジン−８−オンの一水和物および結晶形態
JP7404616B2 (ja) * 2019-03-08 2023-12-26 トランステラ サイエンシーズ （ナンジン）， インコーポレイテッド ホスホジエステラーゼ阻害剤の使用
US20220331304A1 (en) * 2019-07-29 2022-10-20 Constellation Pharmaceuticals, Inc. Compounds for use in treating neurological disorders
WO2024107445A1 (en) * 2022-11-15 2024-05-23 Freedom Biosciences, Inc. Enhancement of the efficacy of serotonergic psychedelic drugs in the treatment or prevention of certain neuropsychiatric disorders through inhibition of type-9 phosphodiesterases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177960A (zh) * 1995-03-10 1998-04-01 圣诺菲药品有限公司 6－取代的吡唑并[3,4－d]嘧啶－4－酮及其组合物和使用方法
GB9722520D0 (en) * 1997-10-24 1997-12-24 Pfizer Ltd Compounds
KR20040053210A (ko) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Ｐｄｅ9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료
SE0103795D0 (sv) 2001-11-02 2001-11-02 Astrazeneca Ab Compounds and method for the treatment of överactive bladder
US20030195205A1 (en) * 2001-11-02 2003-10-16 Pfizer Inc. PDE9 inhibitors for treating cardiovascular disorders
HN2002000317A (es) * 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
JP4464136B2 (ja) * 2001-12-06 2010-05-19 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害薬
GEP20125405B (en) * 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
UA105362C2 (en) * 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators

Also Published As

Publication number Publication date
SI2389382T1 (sl) 2013-07-31
CN102292340B (zh) 2015-05-06
IL213923A (en) 2016-08-31
PT2389382E (pt) 2013-07-15
US8618117B2 (en) 2013-12-31
ZA201105931B (en) 2013-02-27
JP5656874B2 (ja) 2015-01-21
US20120329777A1 (en) 2012-12-27
US20100190771A1 (en) 2010-07-29
TWI404721B (zh) 2013-08-11
TW201028422A (en) 2010-08-01
IL246882A0 (en) 2016-08-31
DK2389382T3 (da) 2013-07-08
EP2389382A1 (en) 2011-11-30
KR20110108415A (ko) 2011-10-05
EP2389382B1 (en) 2013-06-05
AR074966A1 (es) 2011-02-23
MX2011007862A (es) 2011-08-15
AU2010207507A1 (en) 2011-07-21
HK1163092A1 (en) 2012-09-07
AU2010207507B2 (en) 2013-02-07
WO2010084438A1 (en) 2010-07-29
IL213923A0 (en) 2011-07-31
US20140088081A1 (en) 2014-03-27
KR101417237B1 (ko) 2014-07-08
JP2012515761A (ja) 2012-07-12
CA2748864A1 (en) 2010-07-29
HRP20130530T1 (en) 2013-07-31
PL2389382T3 (pl) 2013-09-30
CN102292340A (zh) 2011-12-21
ES2420860T3 (es) 2013-08-27
CA2748864C (en) 2015-03-03
SG172805A1 (en) 2011-08-29
US8278295B2 (en) 2012-10-02

Similar Documents

Publication Publication Date Title
UY32391A (es) Compuestos amino-heterocíclicos
ECSP099728A (es) Compuestos amino-heterocíclicos
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
CO6541656A2 (es) 2-amino-5.5- difluor-5.6-dihidro-4h-oxazinas como inhibidores de bace1 y/o bace 2
SV2006002055A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos ref. pc32054a
CL2009000975A1 (es) Compuestos derivados de quinuclidina, ligandos del receptor de acetilcolina a7; su composicion farmaceutica; su uso para el tratamiento de trastornos del sistema nervioso central, en especial afectivos y neurodegenerativos, enfermedades tales como esquizofrenia y alzheimer.
GT201400301A (es) 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
CO6361910A2 (es) Pirrolidina-2-carboxamidas sustituidas
ECSP13012967A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
UY31405A1 (es) "piperidino-dihidrotienopirimidas sustituidas"
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
UY34239A (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
UY31346A1 (es) Compuestos que tienen actividad en el receptor m1 y sus usos en medicina
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UY31078A1 (es) Compuestos amino-heterociclicos
DOP2012000061A (es) Utilizacion de derivados del indol como activadores de nurr-1, para la aplicacion en tratamientos de enfermedades como el parkinson
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
CY1114108T1 (el) Αμινο-ετεροκυκλικες ενωσεις που χρησιμοποιουνται ως αναστολεις pde9
CU20140021A7 (es) Derivados de 2- amino-4- (piridin-2-il)-5,6- dihidro-4h-1,3- oxacina y su uso como inhibidores de bace -1 y/o bace-2
CL2010001521A1 (es) Compuestos derivados de isoquinolinona sustituidos; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades tales como esquizofrenia, psicosis, alzheimer, entre otras.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181024